Antibody Information

General Information of This Antibody
Antibody ID
ANI0NROSN
Antibody Name
Reverse chimeric (rc) anti-EDB-FN L19
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Fibronectin (FN1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
rcEDB-ADC [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 69.70% (Day 18) High FN1 expression (FN1+++)
Method Description
For studies using the mouse syngeneic cell line EMT6, 8-week-old Balb/c mice were injected in the left mammary fat pad with 1 x106 cells suspended in DPBS. Tumors were measured at least twice/week. This tumor model was injected intravenously with rcEDB-ADC 9 mg/kg single.
In Vivo Model Breast cancer CDX model
In Vitro Model Mammary gland malignant neoplasms EMT6 cells CVCL_1923
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 69.70% (Day 18) High FN1 expression (FN1+++)
Method Description
For studies using the mouse syngeneic cell line EMT6, 8-week-old Balb/c mice were injected in the left mammary fat pad with 1 x106 cells suspended in DPBS. Tumors were measured at least twice/week. This tumor model was injected intravenously with rcEDB-ADC 3 mg/kg q4dx3.
In Vivo Model Breast cancer CDX model
In Vitro Model Mammary gland malignant neoplasms EMT6 cells CVCL_1923
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 69.70% (Day 18) High FN1 expression (FN1+++)
Method Description
For studies using the mouse syngeneic cell line EMT6, 8-week-old Balb/c mice were injected in the left mammary fat pad with 1 x106 cells suspended in DPBS. Tumors were measured at least twice/week. This tumor model was injected intravenously with rcEDB-ADC 1.5 mg/kg q4dx3.
In Vivo Model Breast cancer CDX model
In Vitro Model Mammary gland malignant neoplasms EMT6 cells CVCL_1923
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.30% (Day 18) High FN1 expression (FN1+++)
Method Description
For studies using the mouse syngeneic cell line EMT6, 8-week-old Balb/c mice were injected in the left mammary fat pad with 1 x106 cells suspended in DPBS. Tumors were measured at least twice/week. This tumor model was injected intravenously with rcEDB-ADC 4.5 mg/kg q4dx2.
In Vivo Model Breast cancer CDX model
In Vitro Model Mammary gland malignant neoplasms EMT6 cells CVCL_1923
References
Ref 1 Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade. Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.